Top Searched Resources

FDA Approves New Once-Daily HIV Med Isentress HD

The US FDA has approved a new once-daily version of Merck’s antiretroviral (ARV) Isentress, known as Isentress HD.  Until now, Isentress (raltegravir) had been available only as a twice-daily treatment. Treatment with Isentress HD entails taking two 600 mg tablets once …

Health Consumers Queensland Annual Forum

Queensland Positive People was invited by Health Consumers Queensland to showcase ‘Peer Navigation for People Living with HIV’ at their annual Forum in Townsville, Thursday May 18. The forum, tilted ‘Power and Passion: Culture change through consumer engagement and partnerships,’ showcased …

CROI 2017: Higher than Expected HCV Prevalence Among HIV- Gay Men in Amsterdam PrEP Program

An unexpectedly high number of HIV-negative gay and bisexual men taking pre-exposure prophylaxis (PrEP) in Amsterdam were found to have hepatitis C virus (HCV) infection, suggesting HCV is being transmitted sexually between men with and without HIV, according to a presentation …

ODEFSEY – A NEW TRIPLE COMBO PILL

ODEFSEY – a new combination pill containing rilpivirine (Edurant – an existing NNRTI), TAF (tenofovir alafenamide), and FTC (Emtriva – emtricitabine) was registered in Australia by Gilead Sciences in October 2016, and has now become available (from 01 May 2017) on …

Updated Cervical Cancer Guidelines for Women – Pap Smear Test to be replaced with HPV test

01 March, 2017 -The Medical Services Advisory Committee (MSAC) has provided recommendations on new approaches to cervical screening in Australia. Following a comprehensive review of the current evidence for cervical screening, MSAC has recommended for both Human Papilloma Virus (HPV) vaccinated …

Long Acting HIV Treatment: 5 Myths and Realities

Introduction: Long-acting antiretrovirals: Are they the future of HIV treatment or will the future pass them by? As research progresses on long-acting antiretroviral therapy (LA-ART) for HIV — also sometimes referred to as extended-release (ER) antiretroviral therapy — experts disagree about …